Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG vs Cyclosporine in MDS
NCT00001839Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Dec 1998
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cyclosporine in myelodysplastic syndrome (MDS) (2 arms), sponsored by National Institutes of Health. Primary endpoints: Transfusion Independence and Hematological Response. Started Dec 1998; status: completed.
02
Drugs
cyclosporine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00001839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001839.